Retirement Systems of Alabama increased its position in shares of Eli Lilly and Co. (NYSE:LLY) by 0.0% during the second quarter, Holdings Channel reports. The firm owned 548,522 shares of the company’s stock after buying an additional 81 shares during the period. Retirement Systems of Alabama’s holdings in Eli Lilly and were worth $43,196,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. RNC Capital Management LLC raised its position in Eli Lilly and by 42.4% in the second quarter. RNC Capital Management LLC now owns 410,784 shares of the company’s stock worth $32,349,000 after buying an additional 122,237 shares in the last quarter. Private Capital Advisors Inc. acquired a new position in Eli Lilly and during the second quarter worth approximately $28,535,000. AMP Capital Investors Ltd raised its position in Eli Lilly and by 6.9% in the first quarter. AMP Capital Investors Ltd now owns 512,346 shares of the company’s stock worth $36,776,000 after buying an additional 32,848 shares in the last quarter. Country Trust Bank raised its position in Eli Lilly and by 0.4% in the second quarter. Country Trust Bank now owns 252,356 shares of the company’s stock worth $19,873,000 after buying an additional 909 shares in the last quarter. Finally, Sector Gamma AS raised its position in Eli Lilly and by 89.8% in the first quarter. Sector Gamma AS now owns 771,390 shares of the company’s stock worth $55,548,000 after buying an additional 365,000 shares in the last quarter. 74.96% of the stock is owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Co. (NYSE:LLY) traded down 1.20% during trading on Thursday, hitting $79.74. 3,269,150 shares of the company traded hands. Eli Lilly and Co. has a one year low of $67.88 and a one year high of $88.48. The firm has a 50 day moving average price of $79.24 and a 200-day moving average price of $77.06. The stock has a market cap of $84.34 billion, a price-to-earnings ratio of 34.37 and a beta of 0.20.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The business had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the company earned $0.90 EPS. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. Analysts predict that Eli Lilly and Co. will post $3.59 EPS for the current year.
LLY has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 price objective on the stock in a research note on Friday, August 5th. Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, August 3rd. Argus lifted their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. BMO Capital Markets restated a “buy” rating and issued a $94.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 27th. Finally, Jefferies Group lifted their price objective on shares of Eli Lilly and from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, July 14th. Two research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $97.16.
In related news, major shareholder Lilly Endowment Inc sold 240,000 shares of the stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $82.87, for a total value of $19,888,800.00. Following the sale, the insider now owns 126,020,570 shares of the company’s stock, valued at approximately $10,443,324,635.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jackson P. Tai acquired 5,773 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was purchased at an average cost of $80.43 per share, for a total transaction of $464,322.39. Following the acquisition, the director now owns 42,306 shares in the company, valued at $3,402,671.58. The disclosure for this purchase can be found here. 0.20% of the stock is currently owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.